Medical Care
Global RNA Interference Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 18, 25
- ID: 604867
- Pages: 134
- Figures: 136
- Views: 11
Report Includes:
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global RNA Interference Therapy market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Silence Therapeutics
Arrowhead Pharmaceuticals
Janssen Research & Development
Sylentis
Sirnaomics
Dicerna Pharmaceuticals
Alnylam Pharmaceuticals
Silenseed
Vir Biotechnology
OliX Pharmaceuticals
Bio-Path Holdings
Suzhou Ribo Life Science
Segment by Type
siRNA
miRNA
shRNA
piRNA
Segment by Application
Cancer Treatment
Hereditary Disease
Infectious Disease
Nervous System Disease
Diseases of Immune System
Cardiovascular Disease
Metabolic Disease
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the RNA Interference Therapy study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; top-tier players 2024 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global RNA Interference Therapy market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Silence Therapeutics
Arrowhead Pharmaceuticals
Janssen Research & Development
Sylentis
Sirnaomics
Dicerna Pharmaceuticals
Alnylam Pharmaceuticals
Silenseed
Vir Biotechnology
OliX Pharmaceuticals
Bio-Path Holdings
Suzhou Ribo Life Science
Segment by Type
siRNA
miRNA
shRNA
piRNA
Segment by Application
Cancer Treatment
Hereditary Disease
Infectious Disease
Nervous System Disease
Diseases of Immune System
Cardiovascular Disease
Metabolic Disease
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the RNA Interference Therapy study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; top-tier players 2024 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to RNA Interference Therapy: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global RNA Interference Therapy Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 siRNA
1.2.3 miRNA
1.2.4 shRNA
1.2.5 piRNA
1.3 Market Segmentation by Application
1.3.1 Global RNA Interference Therapy Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Cancer Treatment
1.3.3 Hereditary Disease
1.3.4 Infectious Disease
1.3.5 Nervous System Disease
1.3.6 Diseases of Immune System
1.3.7 Cardiovascular Disease
1.3.8 Metabolic Disease
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global RNA Interference Therapy Revenue Estimates and Forecasts 2020-2031
2.2 Global RNA Interference Therapy Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global RNA Interference Therapy Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global RNA Interference Therapy Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 siRNA Market Size by Players
3.3.2 miRNA Market Size by Players
3.3.3 shRNA Market Size by Players
3.3.4 piRNA Market Size by Players
3.4 Global RNA Interference Therapy Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global RNA Interference Therapy Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global RNA Interference Therapy Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America RNA Interference Therapy Market Size by Type (2020-2031)
6.4 North America RNA Interference Therapy Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America RNA Interference Therapy Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe RNA Interference Therapy Market Size by Type (2020-2031)
7.4 Europe RNA Interference Therapy Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe RNA Interference Therapy Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific RNA Interference Therapy Market Size by Type (2020-2031)
8.4 Asia-Pacific RNA Interference Therapy Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific RNA Interference Therapy Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America RNA Interference Therapy Market Size by Type (2020-2031)
9.4 Central and South America RNA Interference Therapy Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America RNA Interference Therapy Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa RNA Interference Therapy Market Size by Type (2020-2031)
10.4 Middle East and Africa RNA Interference Therapy Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa RNA Interference Therapy Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Silence Therapeutics
11.1.1 Silence Therapeutics Corporation Information
11.1.2 Silence Therapeutics Business Overview
11.1.3 Silence Therapeutics RNA Interference Therapy Product Features and Attributes
11.1.4 Silence Therapeutics RNA Interference Therapy Revenue and Gross Margin (2020-2025)
11.1.5 Silence Therapeutics RNA Interference Therapy Revenue by Product in 2024
11.1.6 Silence Therapeutics RNA Interference Therapy Revenue by Application in 2024
11.1.7 Silence Therapeutics RNA Interference Therapy Revenue by Geographic Area in 2024
11.1.8 Silence Therapeutics RNA Interference Therapy SWOT Analysis
11.1.9 Silence Therapeutics Recent Developments
11.2 Arrowhead Pharmaceuticals
11.2.1 Arrowhead Pharmaceuticals Corporation Information
11.2.2 Arrowhead Pharmaceuticals Business Overview
11.2.3 Arrowhead Pharmaceuticals RNA Interference Therapy Product Features and Attributes
11.2.4 Arrowhead Pharmaceuticals RNA Interference Therapy Revenue and Gross Margin (2020-2025)
11.2.5 Arrowhead Pharmaceuticals RNA Interference Therapy Revenue by Product in 2024
11.2.6 Arrowhead Pharmaceuticals RNA Interference Therapy Revenue by Application in 2024
11.2.7 Arrowhead Pharmaceuticals RNA Interference Therapy Revenue by Geographic Area in 2024
11.2.8 Arrowhead Pharmaceuticals RNA Interference Therapy SWOT Analysis
11.2.9 Arrowhead Pharmaceuticals Recent Developments
11.3 Janssen Research & Development
11.3.1 Janssen Research & Development Corporation Information
11.3.2 Janssen Research & Development Business Overview
11.3.3 Janssen Research & Development RNA Interference Therapy Product Features and Attributes
11.3.4 Janssen Research & Development RNA Interference Therapy Revenue and Gross Margin (2020-2025)
11.3.5 Janssen Research & Development RNA Interference Therapy Revenue by Product in 2024
11.3.6 Janssen Research & Development RNA Interference Therapy Revenue by Application in 2024
11.3.7 Janssen Research & Development RNA Interference Therapy Revenue by Geographic Area in 2024
11.3.8 Janssen Research & Development RNA Interference Therapy SWOT Analysis
11.3.9 Janssen Research & Development Recent Developments
11.4 Sylentis
11.4.1 Sylentis Corporation Information
11.4.2 Sylentis Business Overview
11.4.3 Sylentis RNA Interference Therapy Product Features and Attributes
11.4.4 Sylentis RNA Interference Therapy Revenue and Gross Margin (2020-2025)
11.4.5 Sylentis RNA Interference Therapy Revenue by Product in 2024
11.4.6 Sylentis RNA Interference Therapy Revenue by Application in 2024
11.4.7 Sylentis RNA Interference Therapy Revenue by Geographic Area in 2024
11.4.8 Sylentis RNA Interference Therapy SWOT Analysis
11.4.9 Sylentis Recent Developments
11.5 Sirnaomics
11.5.1 Sirnaomics Corporation Information
11.5.2 Sirnaomics Business Overview
11.5.3 Sirnaomics RNA Interference Therapy Product Features and Attributes
11.5.4 Sirnaomics RNA Interference Therapy Revenue and Gross Margin (2020-2025)
11.5.5 Sirnaomics RNA Interference Therapy Revenue by Product in 2024
11.5.6 Sirnaomics RNA Interference Therapy Revenue by Application in 2024
11.5.7 Sirnaomics RNA Interference Therapy Revenue by Geographic Area in 2024
11.5.8 Sirnaomics RNA Interference Therapy SWOT Analysis
11.5.9 Sirnaomics Recent Developments
11.6 Dicerna Pharmaceuticals
11.6.1 Dicerna Pharmaceuticals Corporation Information
11.6.2 Dicerna Pharmaceuticals Business Overview
11.6.3 Dicerna Pharmaceuticals RNA Interference Therapy Product Features and Attributes
11.6.4 Dicerna Pharmaceuticals RNA Interference Therapy Revenue and Gross Margin (2020-2025)
11.6.5 Dicerna Pharmaceuticals Recent Developments
11.7 Alnylam Pharmaceuticals
11.7.1 Alnylam Pharmaceuticals Corporation Information
11.7.2 Alnylam Pharmaceuticals Business Overview
11.7.3 Alnylam Pharmaceuticals RNA Interference Therapy Product Features and Attributes
11.7.4 Alnylam Pharmaceuticals RNA Interference Therapy Revenue and Gross Margin (2020-2025)
11.7.5 Alnylam Pharmaceuticals Recent Developments
11.8 Silenseed
11.8.1 Silenseed Corporation Information
11.8.2 Silenseed Business Overview
11.8.3 Silenseed RNA Interference Therapy Product Features and Attributes
11.8.4 Silenseed RNA Interference Therapy Revenue and Gross Margin (2020-2025)
11.8.5 Silenseed Recent Developments
11.9 Vir Biotechnology
11.9.1 Vir Biotechnology Corporation Information
11.9.2 Vir Biotechnology Business Overview
11.9.3 Vir Biotechnology RNA Interference Therapy Product Features and Attributes
11.9.4 Vir Biotechnology RNA Interference Therapy Revenue and Gross Margin (2020-2025)
11.9.5 Vir Biotechnology Recent Developments
11.10 OliX Pharmaceuticals
11.10.1 OliX Pharmaceuticals Corporation Information
11.10.2 OliX Pharmaceuticals Business Overview
11.10.3 OliX Pharmaceuticals RNA Interference Therapy Product Features and Attributes
11.10.4 OliX Pharmaceuticals RNA Interference Therapy Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Bio-Path Holdings
11.11.1 Bio-Path Holdings Corporation Information
11.11.2 Bio-Path Holdings Business Overview
11.11.3 Bio-Path Holdings RNA Interference Therapy Product Features and Attributes
11.11.4 Bio-Path Holdings RNA Interference Therapy Revenue and Gross Margin (2020-2025)
11.11.5 Bio-Path Holdings Recent Developments
11.12 Suzhou Ribo Life Science
11.12.1 Suzhou Ribo Life Science Corporation Information
11.12.2 Suzhou Ribo Life Science Business Overview
11.12.3 Suzhou Ribo Life Science RNA Interference Therapy Product Features and Attributes
11.12.4 Suzhou Ribo Life Science RNA Interference Therapy Revenue and Gross Margin (2020-2025)
11.12.5 Suzhou Ribo Life Science Recent Developments
12 RNA Interference TherapyIndustry Chain Analysis
12.1 RNA Interference Therapy Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 RNA Interference Therapy Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global RNA Interference Therapy Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to RNA Interference Therapy: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global RNA Interference Therapy Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 siRNA
1.2.3 miRNA
1.2.4 shRNA
1.2.5 piRNA
1.3 Market Segmentation by Application
1.3.1 Global RNA Interference Therapy Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Cancer Treatment
1.3.3 Hereditary Disease
1.3.4 Infectious Disease
1.3.5 Nervous System Disease
1.3.6 Diseases of Immune System
1.3.7 Cardiovascular Disease
1.3.8 Metabolic Disease
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global RNA Interference Therapy Revenue Estimates and Forecasts 2020-2031
2.2 Global RNA Interference Therapy Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global RNA Interference Therapy Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global RNA Interference Therapy Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 siRNA Market Size by Players
3.3.2 miRNA Market Size by Players
3.3.3 shRNA Market Size by Players
3.3.4 piRNA Market Size by Players
3.4 Global RNA Interference Therapy Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global RNA Interference Therapy Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global RNA Interference Therapy Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America RNA Interference Therapy Market Size by Type (2020-2031)
6.4 North America RNA Interference Therapy Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America RNA Interference Therapy Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe RNA Interference Therapy Market Size by Type (2020-2031)
7.4 Europe RNA Interference Therapy Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe RNA Interference Therapy Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific RNA Interference Therapy Market Size by Type (2020-2031)
8.4 Asia-Pacific RNA Interference Therapy Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific RNA Interference Therapy Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America RNA Interference Therapy Market Size by Type (2020-2031)
9.4 Central and South America RNA Interference Therapy Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America RNA Interference Therapy Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa RNA Interference Therapy Market Size by Type (2020-2031)
10.4 Middle East and Africa RNA Interference Therapy Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa RNA Interference Therapy Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Silence Therapeutics
11.1.1 Silence Therapeutics Corporation Information
11.1.2 Silence Therapeutics Business Overview
11.1.3 Silence Therapeutics RNA Interference Therapy Product Features and Attributes
11.1.4 Silence Therapeutics RNA Interference Therapy Revenue and Gross Margin (2020-2025)
11.1.5 Silence Therapeutics RNA Interference Therapy Revenue by Product in 2024
11.1.6 Silence Therapeutics RNA Interference Therapy Revenue by Application in 2024
11.1.7 Silence Therapeutics RNA Interference Therapy Revenue by Geographic Area in 2024
11.1.8 Silence Therapeutics RNA Interference Therapy SWOT Analysis
11.1.9 Silence Therapeutics Recent Developments
11.2 Arrowhead Pharmaceuticals
11.2.1 Arrowhead Pharmaceuticals Corporation Information
11.2.2 Arrowhead Pharmaceuticals Business Overview
11.2.3 Arrowhead Pharmaceuticals RNA Interference Therapy Product Features and Attributes
11.2.4 Arrowhead Pharmaceuticals RNA Interference Therapy Revenue and Gross Margin (2020-2025)
11.2.5 Arrowhead Pharmaceuticals RNA Interference Therapy Revenue by Product in 2024
11.2.6 Arrowhead Pharmaceuticals RNA Interference Therapy Revenue by Application in 2024
11.2.7 Arrowhead Pharmaceuticals RNA Interference Therapy Revenue by Geographic Area in 2024
11.2.8 Arrowhead Pharmaceuticals RNA Interference Therapy SWOT Analysis
11.2.9 Arrowhead Pharmaceuticals Recent Developments
11.3 Janssen Research & Development
11.3.1 Janssen Research & Development Corporation Information
11.3.2 Janssen Research & Development Business Overview
11.3.3 Janssen Research & Development RNA Interference Therapy Product Features and Attributes
11.3.4 Janssen Research & Development RNA Interference Therapy Revenue and Gross Margin (2020-2025)
11.3.5 Janssen Research & Development RNA Interference Therapy Revenue by Product in 2024
11.3.6 Janssen Research & Development RNA Interference Therapy Revenue by Application in 2024
11.3.7 Janssen Research & Development RNA Interference Therapy Revenue by Geographic Area in 2024
11.3.8 Janssen Research & Development RNA Interference Therapy SWOT Analysis
11.3.9 Janssen Research & Development Recent Developments
11.4 Sylentis
11.4.1 Sylentis Corporation Information
11.4.2 Sylentis Business Overview
11.4.3 Sylentis RNA Interference Therapy Product Features and Attributes
11.4.4 Sylentis RNA Interference Therapy Revenue and Gross Margin (2020-2025)
11.4.5 Sylentis RNA Interference Therapy Revenue by Product in 2024
11.4.6 Sylentis RNA Interference Therapy Revenue by Application in 2024
11.4.7 Sylentis RNA Interference Therapy Revenue by Geographic Area in 2024
11.4.8 Sylentis RNA Interference Therapy SWOT Analysis
11.4.9 Sylentis Recent Developments
11.5 Sirnaomics
11.5.1 Sirnaomics Corporation Information
11.5.2 Sirnaomics Business Overview
11.5.3 Sirnaomics RNA Interference Therapy Product Features and Attributes
11.5.4 Sirnaomics RNA Interference Therapy Revenue and Gross Margin (2020-2025)
11.5.5 Sirnaomics RNA Interference Therapy Revenue by Product in 2024
11.5.6 Sirnaomics RNA Interference Therapy Revenue by Application in 2024
11.5.7 Sirnaomics RNA Interference Therapy Revenue by Geographic Area in 2024
11.5.8 Sirnaomics RNA Interference Therapy SWOT Analysis
11.5.9 Sirnaomics Recent Developments
11.6 Dicerna Pharmaceuticals
11.6.1 Dicerna Pharmaceuticals Corporation Information
11.6.2 Dicerna Pharmaceuticals Business Overview
11.6.3 Dicerna Pharmaceuticals RNA Interference Therapy Product Features and Attributes
11.6.4 Dicerna Pharmaceuticals RNA Interference Therapy Revenue and Gross Margin (2020-2025)
11.6.5 Dicerna Pharmaceuticals Recent Developments
11.7 Alnylam Pharmaceuticals
11.7.1 Alnylam Pharmaceuticals Corporation Information
11.7.2 Alnylam Pharmaceuticals Business Overview
11.7.3 Alnylam Pharmaceuticals RNA Interference Therapy Product Features and Attributes
11.7.4 Alnylam Pharmaceuticals RNA Interference Therapy Revenue and Gross Margin (2020-2025)
11.7.5 Alnylam Pharmaceuticals Recent Developments
11.8 Silenseed
11.8.1 Silenseed Corporation Information
11.8.2 Silenseed Business Overview
11.8.3 Silenseed RNA Interference Therapy Product Features and Attributes
11.8.4 Silenseed RNA Interference Therapy Revenue and Gross Margin (2020-2025)
11.8.5 Silenseed Recent Developments
11.9 Vir Biotechnology
11.9.1 Vir Biotechnology Corporation Information
11.9.2 Vir Biotechnology Business Overview
11.9.3 Vir Biotechnology RNA Interference Therapy Product Features and Attributes
11.9.4 Vir Biotechnology RNA Interference Therapy Revenue and Gross Margin (2020-2025)
11.9.5 Vir Biotechnology Recent Developments
11.10 OliX Pharmaceuticals
11.10.1 OliX Pharmaceuticals Corporation Information
11.10.2 OliX Pharmaceuticals Business Overview
11.10.3 OliX Pharmaceuticals RNA Interference Therapy Product Features and Attributes
11.10.4 OliX Pharmaceuticals RNA Interference Therapy Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Bio-Path Holdings
11.11.1 Bio-Path Holdings Corporation Information
11.11.2 Bio-Path Holdings Business Overview
11.11.3 Bio-Path Holdings RNA Interference Therapy Product Features and Attributes
11.11.4 Bio-Path Holdings RNA Interference Therapy Revenue and Gross Margin (2020-2025)
11.11.5 Bio-Path Holdings Recent Developments
11.12 Suzhou Ribo Life Science
11.12.1 Suzhou Ribo Life Science Corporation Information
11.12.2 Suzhou Ribo Life Science Business Overview
11.12.3 Suzhou Ribo Life Science RNA Interference Therapy Product Features and Attributes
11.12.4 Suzhou Ribo Life Science RNA Interference Therapy Revenue and Gross Margin (2020-2025)
11.12.5 Suzhou Ribo Life Science Recent Developments
12 RNA Interference TherapyIndustry Chain Analysis
12.1 RNA Interference Therapy Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 RNA Interference Therapy Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global RNA Interference Therapy Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global RNA Interference Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global RNA Interference Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global RNA Interference Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global RNA Interference Therapy Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global RNA Interference Therapy Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global RNA Interference Therapy Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global RNA Interference Therapy Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global RNA Interference Therapy by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNA Interference Therapy as of 2024)
Table 11. Global RNA Interference Therapy Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global RNA Interference Therapy Companies Headquarters
Table 13. Global RNA Interference Therapy Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global RNA Interference Therapy Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global RNA Interference Therapy Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global RNA Interference Therapy Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global RNA Interference Therapy Revenue by Application (2026-2031) & (US$ Million)
Table 21. RNA Interference Therapy High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America RNA Interference Therapy Growth Accelerators and Market Barriers
Table 25. North America RNA Interference Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe RNA Interference Therapy Growth Accelerators and Market Barriers
Table 27. Europe RNA Interference Therapy Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific RNA Interference Therapy Growth Accelerators and Market Barriers
Table 29. Asia-Pacific RNA Interference Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America RNA Interference Therapy Investment Opportunities and Key Challenges
Table 31. Central and South America RNA Interference Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa RNA Interference Therapy Investment Opportunities and Key Challenges
Table 33. Middle East and Africa RNA Interference Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Silence Therapeutics Corporation Information
Table 35. Silence Therapeutics Description and Major Businesses
Table 36. Silence Therapeutics Product Features and Attributes
Table 37. Silence Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Silence Therapeutics Revenue Proportion by Product in 2024
Table 39. Silence Therapeutics Revenue Proportion by Application in 2024
Table 40. Silence Therapeutics Revenue Proportion by Geographic Area in 2024
Table 41. Silence Therapeutics RNA Interference Therapy SWOT Analysis
Table 42. Silence Therapeutics Recent Developments
Table 43. Arrowhead Pharmaceuticals Corporation Information
Table 44. Arrowhead Pharmaceuticals Description and Major Businesses
Table 45. Arrowhead Pharmaceuticals Product Features and Attributes
Table 46. Arrowhead Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Arrowhead Pharmaceuticals Revenue Proportion by Product in 2024
Table 48. Arrowhead Pharmaceuticals Revenue Proportion by Application in 2024
Table 49. Arrowhead Pharmaceuticals Revenue Proportion by Geographic Area in 2024
Table 50. Arrowhead Pharmaceuticals RNA Interference Therapy SWOT Analysis
Table 51. Arrowhead Pharmaceuticals Recent Developments
Table 52. Janssen Research & Development Corporation Information
Table 53. Janssen Research & Development Description and Major Businesses
Table 54. Janssen Research & Development Product Features and Attributes
Table 55. Janssen Research & Development Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Janssen Research & Development Revenue Proportion by Product in 2024
Table 57. Janssen Research & Development Revenue Proportion by Application in 2024
Table 58. Janssen Research & Development Revenue Proportion by Geographic Area in 2024
Table 59. Janssen Research & Development RNA Interference Therapy SWOT Analysis
Table 60. Janssen Research & Development Recent Developments
Table 61. Sylentis Corporation Information
Table 62. Sylentis Description and Major Businesses
Table 63. Sylentis Product Features and Attributes
Table 64. Sylentis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Sylentis Revenue Proportion by Product in 2024
Table 66. Sylentis Revenue Proportion by Application in 2024
Table 67. Sylentis Revenue Proportion by Geographic Area in 2024
Table 68. Sylentis RNA Interference Therapy SWOT Analysis
Table 69. Sylentis Recent Developments
Table 70. Sirnaomics Corporation Information
Table 71. Sirnaomics Description and Major Businesses
Table 72. Sirnaomics Product Features and Attributes
Table 73. Sirnaomics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Sirnaomics Revenue Proportion by Product in 2024
Table 75. Sirnaomics Revenue Proportion by Application in 2024
Table 76. Sirnaomics Revenue Proportion by Geographic Area in 2024
Table 77. Sirnaomics RNA Interference Therapy SWOT Analysis
Table 78. Sirnaomics Recent Developments
Table 79. Dicerna Pharmaceuticals Corporation Information
Table 80. Dicerna Pharmaceuticals Description and Major Businesses
Table 81. Dicerna Pharmaceuticals Product Features and Attributes
Table 82. Dicerna Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Dicerna Pharmaceuticals Recent Developments
Table 84. Alnylam Pharmaceuticals Corporation Information
Table 85. Alnylam Pharmaceuticals Description and Major Businesses
Table 86. Alnylam Pharmaceuticals Product Features and Attributes
Table 87. Alnylam Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Alnylam Pharmaceuticals Recent Developments
Table 89. Silenseed Corporation Information
Table 90. Silenseed Description and Major Businesses
Table 91. Silenseed Product Features and Attributes
Table 92. Silenseed Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Silenseed Recent Developments
Table 94. Vir Biotechnology Corporation Information
Table 95. Vir Biotechnology Description and Major Businesses
Table 96. Vir Biotechnology Product Features and Attributes
Table 97. Vir Biotechnology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Vir Biotechnology Recent Developments
Table 99. OliX Pharmaceuticals Corporation Information
Table 100. OliX Pharmaceuticals Description and Major Businesses
Table 101. OliX Pharmaceuticals Product Features and Attributes
Table 102. OliX Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. OliX Pharmaceuticals Recent Developments
Table 104. Bio-Path Holdings Corporation Information
Table 105. Bio-Path Holdings Description and Major Businesses
Table 106. Bio-Path Holdings Product Features and Attributes
Table 107. Bio-Path Holdings Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Bio-Path Holdings Recent Developments
Table 109. Suzhou Ribo Life Science Corporation Information
Table 110. Suzhou Ribo Life Science Description and Major Businesses
Table 111. Suzhou Ribo Life Science Product Features and Attributes
Table 112. Suzhou Ribo Life Science Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Suzhou Ribo Life Science Recent Developments
Table 114. Raw Materials Key Suppliers
Table 115. Distributors List
Table 116. Market Trends and Market Evolution
Table 117. Market Drivers and Opportunities
Table 118. Market Challenges, Risks, and Restraints
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
List of Figures
Figure 1. RNA Interference Therapy Product Picture
Figure 2. Global RNA Interference Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. siRNA Product Picture
Figure 4. miRNA Product Picture
Figure 5. shRNA Product Picture
Figure 6. piRNA Product Picture
Figure 7. Global RNA Interference Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Cancer Treatment
Figure 9. Hereditary Disease
Figure 10. Infectious Disease
Figure 11. Nervous System Disease
Figure 12. Diseases of Immune System
Figure 13. Cardiovascular Disease
Figure 14. Metabolic Disease
Figure 15. RNA Interference Therapy Report Years Considered
Figure 16. Global RNA Interference Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 18. Global RNA Interference Therapy Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 19. Global RNA Interference Therapy Revenue Market Share by Region (2020-2031)
Figure 20. Global RNA Interference Therapy Revenue Market Share Ranking (2024)
Figure 21. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 22. siRNA Revenue Market Share by Player in 2024
Figure 23. miRNA Revenue Market Share by Player in 2024
Figure 24. shRNA Revenue Market Share by Player in 2024
Figure 25. piRNA Revenue Market Share by Player in 2024
Figure 26. Global RNA Interference Therapy Revenue Market Share by Type (2020-2031)
Figure 27. Global RNA Interference Therapy Revenue Market Share by Application (2020-2031)
Figure 28. North America RNA Interference Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 29. North America Top 5 Players RNA Interference Therapy Revenue (US$ Million) in 2024
Figure 30. North America RNA Interference Therapy Revenue (US$ Million) by Type (2020 - 2031)
Figure 31. North America RNA Interference Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 32. US RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 33. Canada RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 34. Mexico RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 35. Europe RNA Interference Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 36. Europe Top 5 Players RNA Interference Therapy Revenue (US$ Million) in 2024
Figure 37. Europe RNA Interference Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 38. Europe RNA Interference Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 39. Germany RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 40. France RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 41. U.K. RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 42. Italy RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 43. Russia RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 44. Asia-Pacific RNA Interference Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 45. Asia-Pacific Top 8 Players RNA Interference Therapy Revenue (US$ Million) in 2024
Figure 46. Asia-Pacific RNA Interference Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 47. Asia-Pacific RNA Interference Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 48. Indonesia RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 49. Japan RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 50. South Korea RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 51. Australia RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 52. India RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 53. Indonesia RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 54. Vietnam RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 55. Malaysia RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 56. Philippines RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 57. Singapore RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 58. Central and South America RNA Interference Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 59. Central and South America Top 5 Players RNA Interference Therapy Revenue (US$ Million) in 2024
Figure 60. Central and South America RNA Interference Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 61. Central and South America RNA Interference Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 62. Brazil RNA Interference Therapy Revenue (2020-2025) & (US$ Million)
Figure 63. Argentina RNA Interference Therapy Revenue (2020-2025) & (US$ Million)
Figure 64. Middle East and Africa RNA Interference Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 65. Middle East and Africa Top 5 Players RNA Interference Therapy Revenue (US$ Million) in 2024
Figure 66. South America RNA Interference Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 67. Middle East and Africa RNA Interference Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 68. GCC Countries RNA Interference Therapy Revenue (2020-2025) & (US$ Million)
Figure 69. Israel RNA Interference Therapy Revenue (2020-2025) & (US$ Million)
Figure 70. Egypt RNA Interference Therapy Revenue (2020-2025) & (US$ Million)
Figure 71. South Africa RNA Interference Therapy Revenue (2020-2025) & (US$ Million)
Figure 72. RNA Interference Therapy Industry Chain Mapping
Figure 73. Channels of Distribution (Direct Vs Distribution)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed
Table 1. Global RNA Interference Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global RNA Interference Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global RNA Interference Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global RNA Interference Therapy Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global RNA Interference Therapy Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global RNA Interference Therapy Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global RNA Interference Therapy Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global RNA Interference Therapy by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNA Interference Therapy as of 2024)
Table 11. Global RNA Interference Therapy Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global RNA Interference Therapy Companies Headquarters
Table 13. Global RNA Interference Therapy Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global RNA Interference Therapy Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global RNA Interference Therapy Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global RNA Interference Therapy Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global RNA Interference Therapy Revenue by Application (2026-2031) & (US$ Million)
Table 21. RNA Interference Therapy High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America RNA Interference Therapy Growth Accelerators and Market Barriers
Table 25. North America RNA Interference Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe RNA Interference Therapy Growth Accelerators and Market Barriers
Table 27. Europe RNA Interference Therapy Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific RNA Interference Therapy Growth Accelerators and Market Barriers
Table 29. Asia-Pacific RNA Interference Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America RNA Interference Therapy Investment Opportunities and Key Challenges
Table 31. Central and South America RNA Interference Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa RNA Interference Therapy Investment Opportunities and Key Challenges
Table 33. Middle East and Africa RNA Interference Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Silence Therapeutics Corporation Information
Table 35. Silence Therapeutics Description and Major Businesses
Table 36. Silence Therapeutics Product Features and Attributes
Table 37. Silence Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Silence Therapeutics Revenue Proportion by Product in 2024
Table 39. Silence Therapeutics Revenue Proportion by Application in 2024
Table 40. Silence Therapeutics Revenue Proportion by Geographic Area in 2024
Table 41. Silence Therapeutics RNA Interference Therapy SWOT Analysis
Table 42. Silence Therapeutics Recent Developments
Table 43. Arrowhead Pharmaceuticals Corporation Information
Table 44. Arrowhead Pharmaceuticals Description and Major Businesses
Table 45. Arrowhead Pharmaceuticals Product Features and Attributes
Table 46. Arrowhead Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Arrowhead Pharmaceuticals Revenue Proportion by Product in 2024
Table 48. Arrowhead Pharmaceuticals Revenue Proportion by Application in 2024
Table 49. Arrowhead Pharmaceuticals Revenue Proportion by Geographic Area in 2024
Table 50. Arrowhead Pharmaceuticals RNA Interference Therapy SWOT Analysis
Table 51. Arrowhead Pharmaceuticals Recent Developments
Table 52. Janssen Research & Development Corporation Information
Table 53. Janssen Research & Development Description and Major Businesses
Table 54. Janssen Research & Development Product Features and Attributes
Table 55. Janssen Research & Development Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Janssen Research & Development Revenue Proportion by Product in 2024
Table 57. Janssen Research & Development Revenue Proportion by Application in 2024
Table 58. Janssen Research & Development Revenue Proportion by Geographic Area in 2024
Table 59. Janssen Research & Development RNA Interference Therapy SWOT Analysis
Table 60. Janssen Research & Development Recent Developments
Table 61. Sylentis Corporation Information
Table 62. Sylentis Description and Major Businesses
Table 63. Sylentis Product Features and Attributes
Table 64. Sylentis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Sylentis Revenue Proportion by Product in 2024
Table 66. Sylentis Revenue Proportion by Application in 2024
Table 67. Sylentis Revenue Proportion by Geographic Area in 2024
Table 68. Sylentis RNA Interference Therapy SWOT Analysis
Table 69. Sylentis Recent Developments
Table 70. Sirnaomics Corporation Information
Table 71. Sirnaomics Description and Major Businesses
Table 72. Sirnaomics Product Features and Attributes
Table 73. Sirnaomics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Sirnaomics Revenue Proportion by Product in 2024
Table 75. Sirnaomics Revenue Proportion by Application in 2024
Table 76. Sirnaomics Revenue Proportion by Geographic Area in 2024
Table 77. Sirnaomics RNA Interference Therapy SWOT Analysis
Table 78. Sirnaomics Recent Developments
Table 79. Dicerna Pharmaceuticals Corporation Information
Table 80. Dicerna Pharmaceuticals Description and Major Businesses
Table 81. Dicerna Pharmaceuticals Product Features and Attributes
Table 82. Dicerna Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Dicerna Pharmaceuticals Recent Developments
Table 84. Alnylam Pharmaceuticals Corporation Information
Table 85. Alnylam Pharmaceuticals Description and Major Businesses
Table 86. Alnylam Pharmaceuticals Product Features and Attributes
Table 87. Alnylam Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Alnylam Pharmaceuticals Recent Developments
Table 89. Silenseed Corporation Information
Table 90. Silenseed Description and Major Businesses
Table 91. Silenseed Product Features and Attributes
Table 92. Silenseed Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Silenseed Recent Developments
Table 94. Vir Biotechnology Corporation Information
Table 95. Vir Biotechnology Description and Major Businesses
Table 96. Vir Biotechnology Product Features and Attributes
Table 97. Vir Biotechnology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Vir Biotechnology Recent Developments
Table 99. OliX Pharmaceuticals Corporation Information
Table 100. OliX Pharmaceuticals Description and Major Businesses
Table 101. OliX Pharmaceuticals Product Features and Attributes
Table 102. OliX Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. OliX Pharmaceuticals Recent Developments
Table 104. Bio-Path Holdings Corporation Information
Table 105. Bio-Path Holdings Description and Major Businesses
Table 106. Bio-Path Holdings Product Features and Attributes
Table 107. Bio-Path Holdings Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Bio-Path Holdings Recent Developments
Table 109. Suzhou Ribo Life Science Corporation Information
Table 110. Suzhou Ribo Life Science Description and Major Businesses
Table 111. Suzhou Ribo Life Science Product Features and Attributes
Table 112. Suzhou Ribo Life Science Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Suzhou Ribo Life Science Recent Developments
Table 114. Raw Materials Key Suppliers
Table 115. Distributors List
Table 116. Market Trends and Market Evolution
Table 117. Market Drivers and Opportunities
Table 118. Market Challenges, Risks, and Restraints
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
List of Figures
Figure 1. RNA Interference Therapy Product Picture
Figure 2. Global RNA Interference Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. siRNA Product Picture
Figure 4. miRNA Product Picture
Figure 5. shRNA Product Picture
Figure 6. piRNA Product Picture
Figure 7. Global RNA Interference Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Cancer Treatment
Figure 9. Hereditary Disease
Figure 10. Infectious Disease
Figure 11. Nervous System Disease
Figure 12. Diseases of Immune System
Figure 13. Cardiovascular Disease
Figure 14. Metabolic Disease
Figure 15. RNA Interference Therapy Report Years Considered
Figure 16. Global RNA Interference Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 18. Global RNA Interference Therapy Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 19. Global RNA Interference Therapy Revenue Market Share by Region (2020-2031)
Figure 20. Global RNA Interference Therapy Revenue Market Share Ranking (2024)
Figure 21. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 22. siRNA Revenue Market Share by Player in 2024
Figure 23. miRNA Revenue Market Share by Player in 2024
Figure 24. shRNA Revenue Market Share by Player in 2024
Figure 25. piRNA Revenue Market Share by Player in 2024
Figure 26. Global RNA Interference Therapy Revenue Market Share by Type (2020-2031)
Figure 27. Global RNA Interference Therapy Revenue Market Share by Application (2020-2031)
Figure 28. North America RNA Interference Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 29. North America Top 5 Players RNA Interference Therapy Revenue (US$ Million) in 2024
Figure 30. North America RNA Interference Therapy Revenue (US$ Million) by Type (2020 - 2031)
Figure 31. North America RNA Interference Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 32. US RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 33. Canada RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 34. Mexico RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 35. Europe RNA Interference Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 36. Europe Top 5 Players RNA Interference Therapy Revenue (US$ Million) in 2024
Figure 37. Europe RNA Interference Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 38. Europe RNA Interference Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 39. Germany RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 40. France RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 41. U.K. RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 42. Italy RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 43. Russia RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 44. Asia-Pacific RNA Interference Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 45. Asia-Pacific Top 8 Players RNA Interference Therapy Revenue (US$ Million) in 2024
Figure 46. Asia-Pacific RNA Interference Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 47. Asia-Pacific RNA Interference Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 48. Indonesia RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 49. Japan RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 50. South Korea RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 51. Australia RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 52. India RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 53. Indonesia RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 54. Vietnam RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 55. Malaysia RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 56. Philippines RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 57. Singapore RNA Interference Therapy Revenue (2020-2031) & (US$ Million)
Figure 58. Central and South America RNA Interference Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 59. Central and South America Top 5 Players RNA Interference Therapy Revenue (US$ Million) in 2024
Figure 60. Central and South America RNA Interference Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 61. Central and South America RNA Interference Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 62. Brazil RNA Interference Therapy Revenue (2020-2025) & (US$ Million)
Figure 63. Argentina RNA Interference Therapy Revenue (2020-2025) & (US$ Million)
Figure 64. Middle East and Africa RNA Interference Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 65. Middle East and Africa Top 5 Players RNA Interference Therapy Revenue (US$ Million) in 2024
Figure 66. South America RNA Interference Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 67. Middle East and Africa RNA Interference Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 68. GCC Countries RNA Interference Therapy Revenue (2020-2025) & (US$ Million)
Figure 69. Israel RNA Interference Therapy Revenue (2020-2025) & (US$ Million)
Figure 70. Egypt RNA Interference Therapy Revenue (2020-2025) & (US$ Million)
Figure 71. South Africa RNA Interference Therapy Revenue (2020-2025) & (US$ Million)
Figure 72. RNA Interference Therapy Industry Chain Mapping
Figure 73. Channels of Distribution (Direct Vs Distribution)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Images Type AIGC Market Research Report 2025
Dec 02, 25
Global Screen Reading Tool for the Blind Market Research Report 2025
Dec 02, 25
Global Full Stack Perception Software Market Research Report 2025
Dec 02, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232